Related references
Note: Only part of the references are listed.Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia
Pamela S. Becker et al.
BLOOD (2009)
Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
B. O. Khatri et al.
NEUROLOGY (2009)
Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
K. Noborio-Hatano et al.
ONCOGENE (2009)
Concurrent Blockade of α4-Integrin and CXCR4 in Hematopoietic Stem/Progenitor Cell Mobilization
Halvard Bonig et al.
STEM CELLS (2009)
Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation
Iskra Pusic et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma
Amanda Cashen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans
Fabian Zohren et al.
BLOOD (2008)
Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab
Halvard Bonig et al.
BLOOD (2008)
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
M. Krumbholz et al.
NEUROLOGY (2008)
Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia
T. Matsunaga et al.
LEUKEMIA (2008)
AMD3100 plus G-CSF can successfully mobilize CD34+cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data
G. Calandra et al.
BONE MARROW TRANSPLANTATION (2008)
Natalizumab for multiple sclerosis
Richard M. Ransohoff
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy -: Possible interventions
Olaf Stuve et al.
ARCHIVES OF NEUROLOGY (2007)
Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma
Frank Kroschinsky et al.
TRANSFUSION (2006)
The role of the α4 integrin-paxillin interaction in regulating leukocyte trafficking
David M. Rose
EXPERIMENTAL AND MOLECULAR MEDICINE (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
RA Rudick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma
I Bruns et al.
TRANSFUSION (2006)
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
N Flomenberg et al.
BLOOD (2005)
Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
BK Kleinschmidt-DeMasters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Anti-α4 integrin therapy for multiple sclerosis -: Mechanisms and rationale
GPA Rice et al.
NEUROLOGY (2005)
Rapid mobilization of CD34+cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma
SM Devine et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Natalizumab for active Crohn's disease.
S Ghosh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease
FH Gordon et al.
GASTROENTEROLOGY (2001)
Combining G-CSF with a blockade of adhesion strongly improves the reconstitutive capacity of mobilized hematopoietic progenitor cells
O Christ et al.
EXPERIMENTAL HEMATOLOGY (2001)
Mobilization of CD34+ haematopoietic stem cells is associated with a functional inactivation of the integrin very late antigen 4
M Lichterfeld et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Share Paper
